Α-Ethyltryptamine

Α-Ethyltryptamine (αET), also known as etryptamine (INN, BAN, USAN), is a psychedelic, stimulant, and entactogenic drug of the tryptamine class. It was originally developed and marketed as an antidepressant under the brand name Monase by Upjohn in the 1960s.

History

Upjohn developed αET in the 1960s as an antidepressant and it was marketed for a short time as Monase. However, it was withdrawn from the market in the early 1970s due to a high incidence of idiosyncratic agranulocytosis.

Pharmacology

αET is a psychedelic, stimulant, and entactogen of the tryptamine class. It shares a close structural relationship with the serotonin molecule, which is primarily responsible for its psychoactive effects.

Legal status

In the United States, αET is a Schedule I controlled substance. This means it has a high potential for abuse, no currently accepted medical use in treatment in the United States, and a lack of accepted safety for use under medical supervision.

See also

• Tryptamine
• Psychedelic drug
• Stimulant
• Entactogen

References

‎ ‎

---

Translate: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, தமிழ், తెలుగు, Urdu, ಕನ್ನಡ, Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, বাংলা
European español, Deutsch, français, Greek, português do Brasil, polski, română, русский, Nederlands, norsk, svenska, suomi, Italian
Middle Eastern & African عربى, Turkish, Persian, Hebrew, Afrikaans, isiZulu, Kiswahili,
Other Bulgarian, Hungarian, Czech, Swedish, മലയാളം, मराठी, ਪੰਜਾਬੀ, ગુજરાતી, Portuguese, Ukrainian